Involvement of platelet-activating factor (PAF) in septic shock and priming as indicated by the effect of hetrazepinoic PAF antagonists

No abstract is available for this paper.

• Publication year

  1991

• Venue

  Lipids

• Publication date

  1991-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/BF02536569PMID 1819735
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Platelet-activating factor type activity in plasma from patients with septicemia and other diseases

  1991cited by this paper
• Beneficial effect of a platelet-activating factor antagonist, WEB 2086, on endotoxin-induced lung injury.

  1990cited by this paper
• Tumor necrosis factor (TNF) and endotoxin prime effects of PAF in vivo.

  1990cited by this paper
• Effect of a new and specific PAF-antagonist, WEB 2086, on PAF and endotoxin/tumor necrosis factor induced changes in mortality and intestinal transit velocity.

  1989cited by this paper
• Platelet-Activating Factor Does Not Mediate Hypoxic Pulmonary Vasoconstriction in the Pig

  1989cited by this paper
• Protective effects of a specific platelet activating factor (PAF) antagonist, WEB 2086, in traumatic shock.

  1989cited by this paper
• Role of cytokines and platelet-activating factor in microvascular immune injury.

  1989cited by this paper
• Occupancy of platelet receptors for platelet-activating factor in patients with septicemia.

  1989cited by this paper
• Hetrazepines as antagonists of platelet activating factor

  1989cited by this paper
• Evidence for Platelet-Activatinc Factor as a Mediator of Hypoxic Pulmonary Vasoconstriction

  1988cited by this paper
• Interaction of fenoterol and web 2086 with propranolol morality in mice and broncho-constriction in the guinea pig to PAF-acether

  1988cited by this paper
• Effect of a new and specific PAF-antagonist, WEB 2086, on PAF and tumor necrosis factor induced changes in mortality and intestinal transit velocity

  1988cited by this paper
• Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet-activating factor

  1987cited by this paper
• The involvement of platelet activating factor in endotoxin‐induced pulmonary platelet recruitment in the guinea‐pig

  1987cited by this paper
• Protective effect of WEB 2086, a novel antagonist of platelet activating factor, in endotoxin shock.

  1987cited by this paper
• The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors.

  1987cited by this paper
• Tumor necrosis factor mediates endotoxic effects in mice

  1987cited by this paper
• Relationship of tumour necrosis factor and endotoxin to macrophage cytotoxicity, haemorrhagic necrosis and lethal shock.

  1987cited by this paper
• Paf‐acether‐induced death in mice: involvement of arachidonate metabolites and β‐adrenoceptors

  1987cited by this paper
• Evidence for platelet-activating factor as a mediator of endotoxin-induced gastrointestinal damage in the rat. Effects of three platelet-activating factor antagonists.

  1987cited by this paper
• Intravascular release of platelet activating factor in children with sepsis.

  1987cited by this paper
• Development of partial tolerance to the gastrointestinal effects of high doses of recombinant tumor necrosis factor-alpha in rodents.

  1987cited by this paper
• Beneficial actions of RO 15-1788, a benzodiazepine receptor antagonist, in hemorrhagic shock.

  1987cited by this paper
• Effect of PAF on the Cardiovascular System

  1987cited by this paper
• Synthesis of PAF-acether and blood volume changes in gram-negative sepsis.

  1985cited by this paper
• Platelet activating factor (PAF) involvement in endotoxin-induced hypotension in rats. Studies with PAF-receptor antagonist kadsurenone.

  1985cited by this paper
• Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin.

  1985cited by this paper
• Glucocorticoid protection against PAF‐acether toxicity in mice

  1983cited by this paper
• β2‐Adrenoceptor blockade is the basis of guinea‐pig bronchial hyper‐responsiveness to leukotriene C4 and other agonists

  1983cited by this paper
• Progress in Clinical and Biological Research

  1979cited by this paper

• Biosynthesis of Phomactin Platelet Activating Factor Antagonist Requires a Two-Enzyme Cascade.

  2023cites this paper
• COVID‐19, microthromboses, inflammation, and platelet activating factor

  2020cites this paper
• Is Platelet-Activating Factor (PAF) a Missing Link for Elucidating the Mechanism of Action of the Coronavirus SARS-CoV-2 and Explaining the Side Effects-Complications of COVID-19 Disease?

  2020influential citation
• In vitro Anti‐atherogenic Properties of N‐Heterocyclic Carbene Aurate(I) Compounds

  2018cites this paper
• A Review on Platelet Activating Factor Inhibitors: Could a New Class of Potent Metal-Based Anti-Inflammatory Drugs Induce Anticancer Properties?

  2017cites this paper
• In vitro effects of vitamin supplements on platelet-activating factor and its metabolism in age-related macular degeneration

  2014cites this paper
• Paricalcitol Effects on Activities and Metabolism of Platelet Activating Factor and on Inflammatory Cytokines in Hemodialysis Patients

  2013cites this paper
• Synthesis, biochemical evaluation and molecular modeling studies of novel rhodium complexes with nanomolar activity against Platelet Activating Factor.

  2013cites this paper
• In vitro anti-inflammatory and anti-coagulant effects of antibiotics towards Platelet Activating Factor and thrombin

  2011influential citation
• In Vitro and In Vivo Effects of Statins on Platelet-Activating Factor and Its Metabolism

  2011cites this paper
• Structurally Diverse Metal Coordination Compounds, Bearing Imidodiphosphinate and Diphosphinoamine Ligands, as Potential Inhibitors of the Platelet Activating Factor

  2010cites this paper
• Regulating inflammation through the anti-inflammatory enzyme platelet-activating factor-acetylhydrolase.

  2005cites this paper
• Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial*

  2004cites this paper
• Should we continue to target the platelet-activating factor pathway in septic patients?

  2004cites this paper
• The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis

  2002cites this paper
• Anti-inflammatory activities of LDP-392, a dual PAF receptor antagonist and 5-lipoxygenase inhibitor.

  2001cites this paper
• A Nozaki-Hiyama-Kishi Ni(II)/Cr(II) coupling approach to the phomactins.

  2001cites this paper
• Enantioselective synthesis of the oxadecalin core of phomactin A via a highly stereoselective Diels-Alder reaction.

  2001cites this paper
• Effect of platelet-activating factor-receptor antagonism on endotoxin-induced lung dysfunction in sheep.

  1998cites this paper
• A pharmacophore for high affinity PAF antagonists. II. Hydrophobicity study using the molecular lipophilicity potential.

  1997cites this paper
• Platelet activating factor antagonism improves cardiovascular function in non-hypotensive sepsis in pigs.

  1996cites this paper
• A pharmacophore for high affinity PAF antagonists. I. Electronic model using molecular electrostatic potential.

  1996cites this paper
• Effects of the platelet‐activating factor receptor antagonist WEB 2086 on whole blood coagulation and fibrinolysis in a thromboelastography assay

  1995cites this paper
• Platelet-activating factor and sepsis-induced small intestinal microvascular hypoperfusion.

  1995cites this paper
• Modulation of lung injury by platelet-activating factor antagonism in nonhypotensive porcine endotoxemia.

  1994cites this paper
• Delayed treatment with platelet activating factor receptor antagonist web 2086 attenuates pulmonary dysfunction in porcine endotoxin shock.

  1994cites this paper
• The effect of SRI 63-675, a competitive platelet-activating factor receptor-antagonist, in the generalized Shwartzman reaction.

  1994cites this paper
• Preclinical studies with platelet-activating factor antagonists in models of septic shock.

  1993cites this paper